Treatment with the EZH2 inhibitor GSK126 effectively reduced the levels of H3K27me3 in melanoma cell lines in a dose dependent manner, leading to a reduction in proliferation, cell cycle arrest and apoptosis. This evidence concerns the gene EZH2 and melanoma.